I am a
Home I AM A Search Login

Papers of the Week


January 27, 2023


Int J Mol Sci


http://www.ncbi.nlm.nih.gov/pubmed/36674537?dopt=Abstract


24


2

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.

Authors

Paroli M, Caccavale R, Paroli M P, Spadea L, Accapezzato D
Int J Mol Sci. 2023 Jan 05; 24(2).
PMID: 36674537.

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral joints, and entheses. This condition causes stiffness, pain, and significant limitation of movement. In recent years, several effective therapies have become available based on the use of biologics that selectively block cytokines involved in the pathogenesis of the disease, such as tumor necrosis factor-α (TNFα), interleukin (IL)-17, and IL-23. However, a significant number of patients show an inadequate response to treatment. Over 10 years ago, small synthetic molecules capable of blocking the activity of Janus kinases (JAK) were introduced in the therapy of rheumatoid arthritis. Subsequently, their indication extended to the treatment of other inflammatory rheumatic diseases. The purpose of this review is to discuss the efficacy and safety of these molecules in axSpA therapy.